Af
No verificado

Affinia Therapeutics

Sobre qué escribimos

BiotecnologíaCardiologíaFarmacéuticaMedicina - VariosSalud
09/10/2026
Eventos
Industria
Salud
Higiene alimentaria
Biotecnología
Medicina - Varios
Farmacéutica
Cardiología
Affinia Therapeutics’ AFTX-201 and UPBEAT™ Clinical Trial in BAG3 DCM Featured at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026
1.00
22/07/2026
Industria
Cardiología
Biotecnología
Farmacéutica
Sanidad
Salud
Higiene alimentaria
Medicina - Varios
FDA Grants Orphan Drug Designation to Affinia Therapeutics’ AFTX-201 for the Treatment of BAG3-Associated Dilated Cardiomyopathy (DCM)
1.00
06/04/2026
Industria
Ciencia
Sanidad
Farmacéutica
VIH, SIDA y enfermedades autoinmunes
Biotecnología
Medicina - Varios
Cardiología
Higiene alimentaria
Salud
Affinia Therapeutics Receives Approval from Health Canada to Initiate the UPBEAT© Trial, a Phase 1/2 Clinical Trial to Investigate AFTX-201 as a Treatment for BAG3-Associated Dilated Cardiomyopathy (DCM)
1.00
04/03/2026
Industria
Ciencia
Higiene alimentaria
Biotecnología
Medicina - Varios
Cardiología
Salud
Farmacéutica
Affinia Therapeutics Granted FDA Fast Track Designation for AFTX-201 as a Treatment for People Living with BAG3-Associated Dilated Cardiomyopathy (DCM)
1.00
18/02/2026
Ciencia
Higiene alimentaria
Biotecnología
Medicina - Varios
Cardiología
Salud
Farmacéutica
Industria
Affinia Therapeutics Receives European Medicines Agency Orphan Drug Designation for AFTX-201 in BAG3-Associated Dilated Cardiomyopathy (DCM)
1.00
04/02/2026
Industria
Ciencia
Higiene alimentaria
Biotecnología
Medicina - Varios
Cardiología
Salud
Farmacéutica
Affinia Therapeutics Announces FDA Acceptance of IND Application to Advance AFTX-201 to a Phase 1/2 Trial for the Treatment of BAG3-Associated Dilated Cardiomyopathy (DCM)
1.00
14/10/2025
Asociaciones/Profesionales
Salud
Biotecnología
Sanidad
Finanzas
Farmacéutica
Cardiología
Eventos
Affinia Therapeutics to Participate in Upcoming Investor Conferences
1.00

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0